Demographic and clinical features of the study participants
A total of 327 adult patients were included in the study. The mean age
was 35±11.1 years and majority of them (62.4%) were female. 73.4%
(n=240), 26.3% (n=86) and 0.3% (n=1) of the patients had AR,
concomitant AR and allergic asthma, and allergic asthma, respectively.
249 (76.1%) patients were sensitive to HDM, 96 (29.3%) were sensitive
to pollen, 8 (2.4%) were sensitive to cat and 1 (0.3%) was sensitive
to mold. The median duration of SCIT was 23 months (IQR 25-75: 10-36
months). During the COVID-19 pandemic, immunotherapy was administered to
151 (46.1%) patients (Group 1) at recommended intervals, 72 (22%)
patients at extended intervals of less than 2 months (Group 2) and 104
(31.8%) patients at extended intervals of at least 2 months (Group 3).
The demographic and clinical features of the patients are shown in
detail in Table 1.